2. Danziger N, Sokol ES, Graf RP, et al. Variable landscape of PD-L1 expression in breast carcinoma as detected by the DAKO 22C3 immunohistochemistry assay. Oncologist. 2023;28(4):319–26. 3. Heater NK, Warrior S, Lu J. Current...
[4] Zhang X, Ge X, Jiang T, Yang R, Li S. Research progress on immunotherapy in triple‑negative breast cancer (Review). Int J Oncol. 2022 Aug;61(2):95. 注:正文大会报告图片来源于2022年ASCO、2022年ESMO大会讲者幻灯。
基于该研究成果,我们开展了卡瑞利珠单抗联合阿帕替尼的“靶免结合”的Ⅱ期临床试验,用于治疗不可手术的复发性或转移性TNBC患者。该方案达到了43.3%的客观缓解率(ORR),且对PD-L1阴性和多线治疗患者也有效,副作用相对较轻,该研究已在《癌症免疫治疗》(Journal for ImmunoTherapy of Cancer)上发表。并且研究中发现PD...
Immunotherapy has had a challenging journey breaking through the breast cancer treatment landscape. Recently, responses have been seen in some patients with triple-negative breast cancer (TNBC), signaling a potential role for immunotherapy in this tumor type. TNBC is a heterogeneous group of breast ...
This research highlights the potential of dual-reprogramming of TIDCs and TAMs with the miR155 nanocomplexes as a promising strategy for TNBC immunotherapy, with potential for translation to other cancers with a similar microenvironment.doi:10.1016/j.ijbiomac.2023.126912Zhenghui Jing...
三阴性乳腺癌(TNBC)约占所有原发性乳腺癌的15%-20%,转移后的中位总生存期仅为13-18个月。由于缺乏特异性的分子靶点,治疗TNBC仍然是一个巨大的挑战。 2023年1月10日,陆军军医大学卞修武及金国祥共同通讯在Cell Research(IF=46)在线发表题为“Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy res...
[3]Yang F, Xiao Y, Ding JH, et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2023;35(1):84-100.e8. doi:10.1016/j.cmet.2022.09.021 [4]Liu CC, Chen L, Cai YW, et al. Targeting EMSY-mediated methionine...
[3]Yang F, Xiao Y, Ding JH, et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2023;35(1):84-100.e8. doi:10.1016/j.cmet.2022.09.021 [4]Liu CC, Chen L, Cai YW, et al. Targeting EMSY-mediated methionine...
Beyond single-agent chemotherapy, few effective treatment options are available for metastatic triple-negative breast cancer (TNBC), according to Candace Mainor, MD, but several approaches comprised of immunotherapy, antibody-drug conjugates (ADCs), and PARP inhibitors are shifting standards of care and...
[3]Yang F, Xiao Y, Ding JH, et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2023;35(1):84-100.e8. doi:10.1016/j.cmet.2022.09.021 [4]Liu CC, Chen L, Cai YW, et al. Targeting EMSY-mediated methionine...